Home / Market News / $UTHR
benzinga Corporate Catalyst Impact 65/100 ● neutral

Goldman Sachs Initiates Coverage On United Therapeutics with Sell Rating, Announces Price Target of $321

Sep 24, 2026, 1:44 PM UTC · Primary ticker $UTHR

Goldman Sachs has initiated coverage on United Therapeutics (UTHR) with a 'Sell' rating and a price target of $321. This analyst action could lead to short-term negative pressure on UTHR's stock as investors react to the bearish outlook from a prominent investment bank.

Goldman Sachs analyst Andrea Newkirk initiated coverage on United Therapeutics (UTHR) with a 'Sell' rating and a $321 price target. This is a significant event for UTHR as a 'Sell' rating from a major investment bank like Goldman Sachs can influence investor sentiment and potentially lead to a downward revision of the stock's valuation by other analysts. The immediate impact is likely negative for UTHR's stock price as investors may sell shares in response to the bearish outlook. In the short term, UTHR could experience increased selling pressure, while the long-term implications depend on whether the market ultimately agrees with Goldman's assessment or if other analysts maintain more positive views. The key risk for traders is a potential decline in UTHR's stock price following this analyst action.

$UTHR negative Initiated with Sell rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.